Sun Pharma’s acquisition of Organon marks a pivot toward biosimilars, utilizing a cheap valuation and strong cash reserves to avoid the chronic post-merger stock slumps seen by Indian rivals.
Recent Posts
- Airlines Likely To Cut Flights On Less Profitable Routes After May ATF Revision
- Jana Nayagan Release Date: When Will Film Hit Theatres? Here’s What Vijay Fans Need To Know
- ‘Leave Him Sleeping’: Iran Again Mocks Trump With Lego-style AI Meme Over War Victory Claim
- Coal India Q4 Review: Jefferies Raises Target Price After Q4 Earnings Beat — Should You Buy, Sell Or Hold? Check Potential Upside
- Gujarat Local Body Election Result 2026 Live: Municipal Corporations Results To Be Out Today